Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 09, 2022 08:00 ET
|
Compass Therapeutics
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...
President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021
August 26, 2021 08:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that...
Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
August 25, 2021 10:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 25, 2021 (GLOBE NEWSWIRE) -- -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
June 29, 2021 11:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
May 26, 2021 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
January 21, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today its...
ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
November 11, 2019 03:21 ET
|
ASLAN PHARMACEUTICALS LIMITED
- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control...
ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
January 29, 2019 17:40 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...
ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI
January 14, 2019 17:44 ET
|
ASLAN Pharmaceuticals Limited
Objective Response Rate of 60% and Disease Control Rate of 100% observed in 300mg dose cohortData demonstrate increased activity of varlitinib in combination with gem/cis compared to standard of care ...
ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
January 02, 2019 03:48 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...